ZUNVEYL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZUNVEYL (ZUNVEYL).
ZUNVEYL is a benzimidazole derivative anthelmintic that binds to β-tubulin in parasitic nematodes, inhibiting microtubule polymerization and disrupting glucose uptake, leading to energy depletion and death of the parasite.
| Metabolism | Primarily hepatic via CYP1A2 and UGT1A1; undergoes first-pass metabolism. |
| Excretion | Primarily renal excretion of unchanged drug (approx. 60-70%) and biliary/fecal elimination (approx. 20-30%). |
| Half-life | Terminal elimination half-life is approximately 12-15 hours, supporting twice-daily dosing. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.3-0.5 L/kg, indicating moderate distribution predominantly in extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 40-50% due to first-pass metabolism. |
| Onset of Action | Oral: Onset of action occurs within 30-60 minutes post-dose. |
| Duration of Action | Duration of action is approximately 12 hours, consistent with twice-daily administration. |
| Molecular Weight | 446.5 |
ZUNVEYL (bendamustine hydrochloride) 100 mg/m² intravenously over 30 minutes on days 1 and 2 of a 28-day cycle, for up to 6 cycles.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | For creatinine clearance (CrCl) 30-39 mL/min: reduce dose to 50 mg/m² on days 1 and 2. For CrCl <30 mL/min: not recommended. No adjustment for CrCl ≥40 mL/min. |
| Liver impairment | For Child-Pugh class A: no adjustment. For Child-Pugh class B: reduce dose to 50 mg/m² on days 1 and 2. For Child-Pugh class C: not recommended. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Geriatric use | No specific dose adjustment required based on age alone; monitor renal function and hematologic toxicity closely, as elderly patients may have increased sensitivity to myelosuppression. |
| 1st trimester | No adequate human data; animal studies show fetal harm. Avoid use in first trimester unless benefits outweigh risks. |
| 2nd trimester | May cause fetal renal impairment and oligohydramnios; use only if clearly needed. |
| 3rd trimester | Risk of neonatal renal dysfunction and respiratory depression; avoid use near term. |
Clinical note
Comprehensive clinical and safety monograph for ZUNVEYL (ZUNVEYL).
| Placental transfer | Crosses placenta in animal models; human data limited but expected due to low molecular weight. |
| Breastfeeding | Not known if excreted in human milk; due to potential for serious adverse reactions, discontinue nursing or drug. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to ZUNVEYL or any componentSevere hepatic impairment (Child-Pugh C)Concurrent use with strong CYP3A4 inducers
| Precautions | Bone marrow suppression (neutropenia, thrombocytopenia) - monitor CBC during prolonged therapy, Hepatotoxicity - monitor liver enzymes, Risk of metabolic acidosis in children <2 years, Seizure risk in patients with hepatic impairment, Use in pregnancy: Category C (avoid in first trimester unless potential benefit outweighs risk) |
| Food/Dietary | No specific food interactions reported. However, grapefruit juice may potentially increase buprenorphine levels due to CYP3A4 inhibition; consider reducing intake. Avoid alcohol consumption as it can increase the risk of CNS depression and respiratory depression. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | ZUNVEYL (bupivacaine liposome) is classified as FDA Pregnancy Category C. Animal studies have shown adverse effects on fetal development at doses similar to human doses. In the first trimester, there is a potential risk for teratogenicity, though no adequate human studies exist. In the second and third trimesters, use may be associated with fetal bradycardia, acidosis, and central nervous system depression due to placental transfer. Avoid use during pregnancy unless clearly needed. |
| Fetal Monitoring | Monitor maternal vital signs, including heart rate and blood pressure, continuously during administration. Assess fetal heart rate patterns throughout labor if used for obstetric anesthesia. Monitor for signs of local anesthetic systemic toxicity (LAST) in the mother, including neurological and cardiovascular symptoms. In neonates, observe for respiratory depression, bradycardia, and hypotonia if given near delivery. |
| Fertility Effects | Reproductive studies in animals have not demonstrated impaired fertility at clinically relevant doses. However, no well-controlled human studies are available. Bupivacaine is not known to directly affect human spermatogenesis or oogenesis. Use of ZUNVEYL may indirectly impact fertility if used for procedures affecting reproductive organs, but no direct fertility effects have been reported. |
| Clinical Pearls | ZUNVEYL (buprenorphine extended-release injection) is a Schedule III partial mu-opioid agonist indicated for opioid use disorder. Avoid use in patients with significant respiratory depression or acute asthma. Due to its long half-life (24-42 days after injection), dose adjustments or discontinuation require careful planning. Monitor for injection site reactions (pain, swelling, induration) and hepatic function. Coadministration with benzodiazepines or CNS depressants increases risk of respiratory depression; consider dose reduction or alternative therapy. Naloxone may not fully reverse buprenorphine effects; high doses may be needed. Do not use in patients with moderate to severe hepatic impairment (Child-Pugh B or C). |
| Patient Advice | ZUNVEYL is a monthly injection given by a healthcare provider to treat opioid dependence. · It contains buprenorphine, which can cause respiratory depression, especially if combined with alcohol, benzodiazepines, or other sedatives. · Do not attempt to self-inject; the medication is administered only by a healthcare professional. · Inform your doctor if you have liver problems, asthma, or a history of head injury. · Avoid driving or operating heavy machinery until you know how ZUNVEYL affects you. · Seek immediate medical attention if you experience difficulty breathing, excessive drowsiness, or signs of allergic reaction (rash, swelling). · Do not use illicit opioids or other drugs while on ZUNVEYL; this can cause severe withdrawal or overdose. · Keep all appointments for injections; missing doses may lead to withdrawal symptoms. · Store the medication at room temperature; do not freeze. · You may experience injection site reactions; notify your provider if pain or swelling persists. |